Szigethy Endre, Merzah Mohammed, Sola Ivan, Urrútia Gerard, Bonfill Xavier
PhD Programme in Biomedical Research Methodology and Public Health, Universitat Autònoma de Barcelona, Barcelona, Spain.
Epidy Kft, Csúcs Utca 9, Debrecen, 4034, Hungary.
Clin Transl Oncol. 2025 May;27(5):1980-1993. doi: 10.1007/s12094-024-03711-1. Epub 2024 Oct 5.
This scoping review aims to deepen the understanding of end-of-life anticancer drug use in lung cancer patients, a disease marked by high mortality and symptom burden. Insight into unique end-of-life treatment patterns is crucial for improving the appropriateness of cancer care for these patients.
Comprehensive searches were carried out in Medline and Embase to find articles on the utilization of anticancer drugs in the end of life of lung cancer patients.
We identified 68 publications, highlighting the methodological characteristics of studies including the timing of the research, disease condition, treatment regimen, type of treatment, and features of the treatment. We outlined the frequency of anticancer drug use throughout different end-of-life periods.
This review provides a comprehensive overview of primary studies exploring end-of-life treatments in lung cancer patients. Methodological inconsistencies pose many challenges, revealing a notable proportion of patients experiencing potential overtreatment, warranting more standardized research methods for robust evaluations.
本综述旨在加深对肺癌患者临终时抗癌药物使用情况的理解，肺癌是一种死亡率高且症状负担重的疾病。深入了解独特的临终治疗模式对于提高这些患者的癌症护理适宜性至关重要。
在Medline和Embase中进行全面检索，以查找关于肺癌患者临终时抗癌药物使用情况的文章。
我们确定了68篇出版物，突出了研究的方法学特征，包括研究时间、疾病状况、治疗方案、治疗类型和治疗特点。我们概述了不同临终阶段抗癌药物的使用频率。
本综述全面概述了探索肺癌患者临终治疗的主要研究。方法学上的不一致带来了许多挑战，表明相当一部分患者可能接受了过度治疗，这需要更标准化的研究方法来进行有力评估。
